Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug aims to slow vision loss from dry macular degeneration

NCT ID NCT05839041

Disease control Sponsor: Aviceda Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times

Summary

This study tests an experimental drug called AVD-104, given as an eye injection, for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The trial involves 300 participants and aims to see if the drug is safe and can slow the growth of damaged areas in the eye. It is not a cure, but may help control the disease and preserve vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

300 people

The number who actually took part.

Started

May 2023

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Part 1: 1. BCVA in the study eye using ETDRS Chart Visual Acuity Scale (VAS) of 5 to 55 letters (equivalent to Snellen VA of approximately 20/800 - 20/80) 2. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA) 3. GA may be center involved. Part 2: 1. BCVA in the study eye using ETDRS Chart VAS of 24 letters or better (equivalent to Snellen VA of 20/320 or better) 2. Confirmed diagnosis of AMD that is non-center involving (i.e., non-sub-foveal) GA in 50% of participants. Center involvement allowed in 50% of participants. 3. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: Part 1 and 2 \- Presence of the following ocular conditions - in the Study Eye: 1. Exudative AMD or choroidal neovascularization (CNV), including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere based on spectral domain optical coherence tomography (SD-OCT) imaging and/or fluorescein angiography as assessed by the Reading Center. 2. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the Investigator, could compromise visual function during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy of the macula are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy of the macula Macular degeneration

Contacts and locations

Locations

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona, 85021, United States

  • Associated Retina Consultants

    Gilbert, Arizona, 85297, United States

  • Associated Retina Consultants

    Scottsdale, Arizona, 85260, United States

  • Associated Retinal Consultants

    Royal Oak, Michigan, 48073, United States

  • Austin Retina Associates

    Austin, Texas, 78705, United States

  • Center for Retina & Macular Disease

    Winter Haven, Florida, 33880, United States

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland, 21740, United States

  • Erie Retina Research, LLC

    Erie, Pennsylvania, 16507, United States

  • Florida Retina Institute

    Orlando, Florida, 32806, United States

  • Illinois Retina Associates

    Oak Park, Illinois, 60304, United States

  • Kaiser Permanente

    Riverside, California, 92505, United States

  • Long Island Vitreoretinal Consultants

    Westbury, New York, 11590, United States

  • Macula & Retina Institute

    Glendale, California, 91203, United States

  • Mid-Atlantic Retina

    Bethlehem, Pennsylvania, 18017, United States

  • Midwest Eye Institute

    Indianapolis, Indiana, 46290, United States

  • Mississippi Retina Associates

    Jackson, Mississippi, 39202, United States

  • NJ Retina

    Edison, New Jersey, 08820, United States

  • New England Retina Consultants

    Springfield, Massachusetts, 01107, United States

  • North Carolina Retina Associates

    Wake Forest, North Carolina, 27587, United States

  • Northern California Retina Vitreous Associates

    Mountain View, California, 94040, United States

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114, United States

  • Palmetto Retina Center

    West Columbia, South Carolina, 29169, United States

  • RCA: California Retina Consultants

    Santa Barbara, California, 93103, United States

  • Rand Eye Institute

    Deerfield Beach, Florida, 33064, United States

  • Retina Associates of Cleveland

    Cleveland, Ohio, 44130, United States

  • Retina Associates of Cleveland, Inc

    Beachwood, Ohio, 44122, United States

  • Retina Center of New Jersey

    Bloomfield, New Jersey, 07003, United States

  • Retina Consultants of Charleston

    Charleston, South Carolina, 29414, United States

  • Retina Consultants of Minnesota

    Minneapolis, Minnesota, 55435, United States

  • Retina Consultants of Texas

    San Antonio, Texas, 78240, United States

  • Retina Consultants of Texas

    San Antonio, Texas, 78503, United States

  • Retina Consultants of Texas

    The Woodlands, Texas, 77384, United States

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231, United States

  • Retina Group of Florida

    Fort Lauderdale, Florida, 33308, United States

  • Retina Group of New England, PC

    Waterford, Connecticut, 06385, United States

  • Retina Research Institute of Texas Abilene TX

    Abilene, Texas, 79606, United States

  • Retina Specialists of Michigan

    Grand Rapids, Michigan, 49546, United States

  • Retina Specialty Institute

    Pensacola, Florida, 32503, United States

  • Retina Vitreous Associates Medical Group

    Beverly Hills, California, 90211, United States

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida, 33711, United States

  • Retina Vitreous Center

    Edmond, Oklahoma, 73013, United States

  • Retina-Vitreous Surgeons of Central NY

    Syracuse, New York, 13088, United States

  • Retinal Consultants Medical Group

    Sacramento, California, 95841, United States

  • Retinal Consultants Medical Group, Inc.

    Sacramento, California, 95825, United States

  • Rocky Mountain Retina Consultants

    Salt Lake City, Utah, 84107, United States

  • Sierra Eye Associates

    Reno, Nevada, 89502, United States

  • Southeast Retina Center

    Augusta, Georgia, 30909, United States

  • Southern Vitreoretinal Associates

    Tallahassee, Florida, 32308, United States

  • Spokane Eye Clinic

    Spokane, Washington, 99204, United States

  • Tennessee Retina

    Nashville, Tennessee, 37203, United States

  • Texas Retina Associates

    Arlington, Texas, 76012, United States

  • Texas Retina Associates

    Dallas, Texas, 75231, United States

  • Texas Retina Associates

    Fort Worth, Texas, 76104, United States

  • University Retina and Macula Associates

    Chicago, Illinois, 60439, United States

  • Valley Retina Institute

    McAllen, Texas, 78504, United States

  • West Coast Retina

    San Francisco, California, 94101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.